InvestorsHub Logo

norisknorewards

04/04/24 11:56 AM

#683180 RE: bas2020 #683179

thats fine, let them flop and miss

UK will embarrass them shortly

manibiotech

04/04/24 11:57 AM

#683181 RE: bas2020 #683179

They can only focus on what is submitted to them to be reviewed . That can’t plead the companies to submit

CrashOverride

04/04/24 12:14 PM

#683183 RE: bas2020 #683179

FDA will rapidly approve DCVax as our data are far more robust than toxic yet approved CAR-T. NWBO applied to UK because first they're very familiar with DCVax via the Specials Program. If US had similar innovations more than a decade ago we could have applied here before the UK.

Under Orbis MHRA can refer our application to all other regulatory authorities (RAs) without need for NWBO to submit separate applications to other RAs.

The notion that FDA prefers mRNA over DCVax isn't true. mRNA simply has greater awareness due to Covid-19. We have superior technology by far. It will be approved without issue.

DCVax:

- nontoxic
- efficacious
- cost effective


Take that to the bank.